Biovitrum AB Begins Exinalda(TM) Study with Cystic Fibrosis Patients with Fat Malabsorption

Stockholm September 16, 2008 - Biovitrum AB (publ) (STO:BVT) reported today the start of a clinical phase II study with Exinalda(TM), a candidate drug for the treatment of fat malabsorption. The aim of the study is to document the clinical effect of Exinalda in patients with pancreatic insufficiency as the result of cystic fibrosis. The study comprises 18 patients and is being conducted in Poland and the Netherlands. The results of the study are expected during the first half of 2009.

Biovitrum develops Exinalda as an enzyme replacement treatment for patients with fat malabsorption due to pancreatic insufficiency as a result of, for example, cystic fibrosis (CF). Exinalda is a biotechnically produced version of a human fat-digesting enzyme (bile salt stimulated lipase; BSSL); an enzyme that these patients lack.

"We are pleased to see our portfolio of specialist projects further mature. We currently have seven specialist drugs on the market and six candidates in our R&D portfolio, including Exinalda. Our strategy focuses on taking candidate drugs all the way to the market and then handling the marketing of these drugs ourselves," says Martin Nicklasson, CEO of Biovitrum.

For more information, please contact:

Biovitrum AB (publ) Erik Walum, Director Science Communication Phone: +46 8 697 32 40 erik.walum@biovitrum.com